<DOC>
	<DOCNO>NCT00124189</DOCNO>
	<brief_summary>The purpose study determine safety maximum tolerate dose GRN163L treat patient refractory relapse chronic lymphoproliferative disease .</brief_summary>
	<brief_title>Safety Dose Study GRN163L Treat Patients With Chronic Lymphoproliferative Disease ( CLD )</brief_title>
	<detailed_description>Imetelstat Sodium ( GRN163L ) telomerase template antagonist vitro vivo activity variety tumor model system . Telomerase enzyme active primarily tumor cell crucial indefinite growth tumor cell . Inhibition telomerase may result antineoplastic effect . High telomerase level short telomere lengths correlate marker poor prognosis patient chronic lymphoproliferative disease .</detailed_description>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>18 year age old Male female Chronic lymphoproliferative disease relate biology similar clinical pattern BCell Leukemia ( CLL ) include : small lymphocytic lymphoma ( SLL ) , T cell prolymophocytic leukemia ( TPLL ) , B cell prolymphocytic leukemia ( BPLL ) , mantle cell lymphoma nonHodgkins lymphoma leukemic phase ( peripheral blood circulate malignant cell present ) , Waldenstrom 's macroglobulinemia Must relapse refractory prior therapeutic regimen Patients CLL SLL must receive least one prior purine analoguebased chemotherapy regimen ( eg , fludarabine , pentostatin cladribine ) If previously treat anthracycline , anthracenedione , trastuzumab , must leave ventricular ejection fraction &gt; 50 % ECOG performance status 02 Life expectancy 3 month great Pregnant lactate woman Active 2nd malignancy history another malignancy within 2 year , except : treat , nonmelanoma skin cancer , treat breast cervical carcinoma situ , resect T1a b prostate cancer Chemotherapeutic agent within 4 week prior study High dose CTX stem cell support within 6 month prior study Signal transduction inhibitor , monoclonal antibody within 4 week prior study Immunotherapy biological response modifier within 4 week prior study Systemic hormonal therapy within 4 week prior study Anticoagulant therapy , antiplatelet therapy within 2 week prior study Radiotherapy within 4 week prior study Active autoimmune disorder Central nervous system leptomeningeal involvement Clinically significant cardiovascular disease Known HIV infection Serious/active infection Surgical procedure within 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>T-cell prolymphocytic leukemia</keyword>
	<keyword>Chronic lymphoproliferative disease</keyword>
	<keyword>Telomerase</keyword>
	<keyword>Telomerase Inhibition</keyword>
</DOC>